MORE►
dallas biotech funding
R.A. Session II
Success in the Genes: Launching in a Pandemic Didn’t Hurt This Fast-Growth Dallas Biotech Company
by Quincy Preston | Feb 26, 2021
In under six months, Taysha Gene Therapies rocketed from the unveiling of its UTSW spinout to a $157 million initial public offering. We talk with Founder and CEO R.A. Session II about the biotech with big plans.
by Alex Edwards |
Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE►
![R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]](https://s24806.pcdn.co/wp-content/uploads/2020/04/TayshaGene-Session-970-1-360x203.jpg)
by Quincy Preston and Alex Edwards |
Aug 5, 2020
Taysha Gene Therapies, which was been operating in stealth with UT Southwestern until this April, plans to use the financing to advance its initial cohort of lead programs into its clinic. By the end of 2021, Taysha expects to file four Investigational New Drug applications.
MORE►
